Can Zaynich help Wockhardt turn Indian antibiotic innovation into a global commercial platform?
Find out how Wockhardt’s Zaynich FDA approval could reshape Indian pharma innovation and the fight against drug-resistant infections.
Nacubactam trial win gives Meiji Seika Pharma a stronger AMR case, but approval hurdles remain
Antibiotic resistance needs new tools. Meiji Seika Pharma’s nacubactam now has Phase III data, but regulators must judge its real-world fit.